Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common shares, Euro 0.12 nominal value per share
-
Shares outstanding
-
26.3M
-
Number of holders
-
16
-
Total 13F shares, excl. options
-
7.84M
-
Shares change
-
-156K
-
Total reported value, excl. options
-
$22.8M
-
Value change
-
-$450K
-
Number of buys
-
2
-
Number of sells
-
-9
-
Price
-
$2.95
Significant Holders of LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) as of Q2 2022
17 filings reported holding LVTX - LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share as of Q2 2022.
LAVA Therapeutics NV - Common shares, Euro 0.12 nominal value per share (LVTX) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 7.84M shares
of 26.3M outstanding shares and own 29.79% of the company stock.
Largest 10 shareholders include Novo Holdings A/S (3.33M shares), Redmile Group, LLC (2.82M shares), Nicholas Investment Partners, LP (451K shares), Nantahala Capital Management, LLC (323K shares), AXA S.A. (227K shares), Artal Group S.A. (200K shares), DAFNA Capital Management LLC (128K shares), Alpha Wave Global, LP (121K shares), Point72 Asset Management, L.P. (112K shares), and MILLENNIUM MANAGEMENT LLC (96.4K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.